Highest-materiality recent filing
Editas Medicine prices $125M public offering of shares and warrants
Priced 55,555,556 shares and warrants at $2.25 per unit; gross proceeds $125M before warrant exercise.
EDIT-401 preclinical data shows ~90% mean reductions in LDL-C, Lp(a), ApoB in NHPs
Single dose achieved ≥90% mean reduction in LDL-C, rapid and dose-dependent, durable through 6 months in NHPs.
Editas reports EDIT-401 achieves ≥90% LDL-C reduction in NHPs; durable through 6 months
Single dose of EDIT-401 achieved ≥90% mean LDL-C reduction across all dose groups in non-human primates.
Editas Q1 net loss $25M ($0.26/share); EDIT-401 on track for human data by year-end
Net loss of $25.0M ($0.26 per share) vs. $76.1M ($0.92) in Q1 2025; no restructuring charges this quarter.
USPTO reaffirms Broad Institute's CRISPR/Cas9 patent priority; Editas' licensed patents upheld
PTAB issued third favorable decision for Broad over CVC on CRISPR/Cas9 editing in eukaryotic cells.
Editas Medicine Q4 2025 net loss $5.6M; EDIT-401 IND on track mid-2026
Cash $146.6M at Dec 31, 2025, down from $269.9M; runway into Q3 2027.
Net loss of $25.1M ($0.28/sh) vs $62.1M ($0.75/sh) in Q3 2024; collaboration revenue rose to $7.5M from $0.1M on BMS milestone.
Editas reports in vivo proof-of-concept for EDIT-401 with ≥90% LDL-C reduction in NHPs
EDIT-401 achieved ≥90% mean LDL-C reduction in non-human primates within 48 hours of a single dose.
Editas Medicine nominates EDIT-401 as lead in vivo candidate; ~90% LDL-C reduction in NHPs
EDIT-401 achieved ~90% mean LDL-C reduction after single dose in non-human primates across all doses (1.5-4 mg/kg), sustained for one month.
Editas Q2 net loss $53.2M; selects in vivo lead candidate in Sept; BMS CAR T milestone triggered
Q2 net loss $53.2M ($0.63/share) vs $67.6M loss a year ago; revenue $3.6M from BMS milestone.
Editas reports 58% HBG1/2 editing in NHPs after single tLNP dose at 5 months
Mean on-target editing of 58% in HSCs at 5 months post single IV dose of proprietary tLNP, exceeding ≥25% therapeutic threshold.
Editas reports in vivo HSC editing up to 48% HBG1/2, exceeding 25% therapeutic threshold
Single dose of proprietary tLNP achieved up to 47% HBG1/2 editing in NHP HSCs and 48% in humanized mouse long-term HSCs.
Editas Q1 net loss $76.1M ($0.92/share); cash $221M runway into Q2 2027
Net loss $76.1M ($0.92 per share) vs $62.0M loss in Q1 2024; revenue $4.7M (up from $1.1M).
Editas Medicine CFO resigns; Amy Parison appointed as CFO
Erick Lucera resigns as EVP, CFO effective March 28, 2025.
Editas posts Q4 net loss $45.4M ($0.55/sh); ends reni-cel, cuts 65% staff
Q4 2024 net loss $45.4M vs $18.9M in Q4 2023; full-year net loss $237.1M vs $153.2M.
Editas Medicine reports $270M cash, new in vivo preclinical data, and 2025-2027 strategic priorities
Preliminary cash, equivalents, marketable securities ~$270M as of Dec 31, 2024; operational runway into Q2 2027.
Editas halts reni-cel, cuts 65% workforce, shifts to in vivo gene editing
Discontinues ex vivo reni-cel program for sickle cell and beta thalassemia; ends partnering process.
Editas reports positive RUBY trial data: 27/28 SCD patients VOE-free, HbF 48% at month 6
As of Oct 29, 2024, 28 SCD patients treated; 27 VOE-free post-reni-cel; median follow-up 9.5 months.
Editas Q3 net loss widens to $62.1M; cash runway extended into Q2 2026
Q3 2024 net loss of $62.1M ($0.75/sh) vs $45.0M ($0.55/sh) in Q3 2023; R&D spend up $7.1M.
Editas achieves in vivo preclinical proof of concept for sickle cell; seeks partner for reni-cel
Achieved 29% HSPC editing and 20% HbF-expressing red blood cells in humanized mice after single dose using proprietary tLNP.
Editas Medicine monetizes Vertex license fees for $57M upfront from DRI Healthcare Trust
Upfront cash payment of $57M from DRI subsidiary for up to 100% of future annual license fees ($5M-$40M/year) and a mid-double-digit % of $50M contingent payment under Vertex Cas9 license.
Net loss $67.6M ($0.82 per share) vs $40.3M ($0.56 per share) in Q2 2023.
Editas reni-cel RUBY trial: 18 SCD patients VOE-free; EdiTHAL: 7 TDT patients transfusion-free
18 SCD patients free of vaso-occlusive events post-reni-cel (follow-up 2.4-22.8 months); mean total Hb >14 g/dL, HbF >40%.
Editas Medicine Q1 net loss $62M; cash $376.8M; reni-cel adult cohort enrollment complete
Q1 2024 net loss $62.0M ($0.76/share) vs $49.0M ($0.71) in Q1 2023; collaboration revenue fell to $1.1M from $9.9M.
Editas reports Q4 net loss of $18.9M; Vertex license deal provides cash runway into 2026
Q4 net loss $18.9M ($0.23 per share) vs $60.7M ($0.88) in Q4 2022; revenue boosted by Vertex license.
On March 18, 2025, Erick Lucera, Executive Vice President, Chief Financial Officer of Editas Medicine, Inc. (the “Company”) informed the Company that he will be resigning from his position effective March 28, 2025.
In connection with Mr. Lucera’s resignation, on March 19, 2025 the Company appointed Amy Parison, Senior Vice President, Finance as Senior Vice President, Chief Financial Officer and Treasurer of the Company, to be effective as of the close of business on March 28, 2025.
On June 27, 2024, Akshay Vaishnaw informed the Board of Directors (the “Board”) of Editas Medicine, Inc. (the “Company”) of his resignation from the Board effective as of June 30, 2024.
Max materiality 0.85 · Median 0.68 · Most common event other_material